60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has a cash flow conversion efficiency ratio of -0.883x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.23 Million) by net assets ($2.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 60 Degrees Pharmaceuticals, Inc. Common (SXTP) total market value for the company's overall valuation and market capitalisation.
60 Degrees Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore cash flow quality index of 60 Degrees Pharmaceuticals, Inc. Common to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Martela Oyj A
HE:MARAS
|
0.082x |
|
URU METALS LTD
F:NVRA
|
N/A |
|
QEM Ltd
AU:QEM
|
-0.341x |
|
De La Rue PLC
LSE:DLAR
|
2.021x |
|
Psyence Biomedical Ltd. Common Shares
NASDAQ:PBM
|
0.000x |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
0.002x |
|
Birddog Technology Ltd
AU:BDT
|
-0.302x |
|
Haffner Energy SA
PA:ALHAF
|
-0.330x |
Annual Cash Flow Conversion Efficiency for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. View 60 Degrees Pharmaceuticals, Inc. Common share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.38 Million | $-6.85 Million | -2.027x | -41.92% |
| 2024-12-31 | $3.96 Million | $-5.65 Million | -1.428x | -50.83% |
| 2023-12-31 | $4.80 Million | $-4.54 Million | -0.947x | -2363.88% |
| 2022-12-31 | $-24.15 Million | $-1.01 Million | 0.042x | +16.97% |
| 2021-12-31 | $-18.15 Million | $-649.11K | 0.036x | +286.20% |
| 2020-12-31 | $-18.07 Million | $-167.30K | 0.009x | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more